Tempus AI (NASDAQ:TEM) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

Tempus AI (NASDAQ:TEM) had its target price boosted by analysts at Cantor Fitzgerald from $80.00 to $92.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald‘s target price would indicate a potential upside of 17.23% from the stock’s current price.

Other equities analysts also recently issued research reports about the stock. Stifel Nicolaus lowered their target price on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating on the stock in a report on Monday, August 3rd. UBS Group assumed coverage on shares of Tempus AI in a research note on Wednesday, September 9th. They set a “neutral” rating and a $70.00 target price for the company. Needham & Company LLC raised their target price on shares of Tempus AI from $75.00 to $89.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings upgraded shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 13th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Tempus AI from $45.00 to $70.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 14th. Eleven research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Tempus AI currently has an average rating of “Hold” and a consensus price target of $79.37.

Tempus AI Stock Performance

Shares of TEM opened at $78.48 on Tuesday. The business has a 50-day simple moving average of $70.80 and a two-hundred day simple moving average of $57.12. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. Tempus AI has a 52 week low of $40.77 and a 52 week high of $90.53. The stock has a market cap of $14.16 billion, a price-to-earnings ratio of -54.50 and a beta of 3.54.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Monday, November 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16. The firm had revenue of $411.54 million during the quarter, compared to analysts’ expectations of $409.39 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company’s revenue for the quarter was up 23.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.46) earnings per share. On average, analysts expect that Tempus AI will post -1.45 EPS for the current year.

Insider Activity at Tempus AI

In other news, EVP Andrew Polovin sold 2,951 shares of the stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $75.00, for a total value of $221,325.00. Following the sale, the executive vice president owned 135,189 shares of the company’s stock, valued at approximately $10,139,175. This represents a 2.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nadja West sold 3,000 shares of the firm’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $69.00, for a total transaction of $207,000.00. Following the completion of the sale, the director directly owned 31,981 shares of the company’s stock, valued at approximately $2,206,689. The trade was a 8.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,256,777 shares of company stock worth $86,356,352 in the last ninety days. Corporate insiders own 24.26% of the company’s stock.

Hedge Funds Weigh In On Tempus AI

Institutional investors have recently made changes to their positions in the company. Sumitomo Mitsui Trust Group Inc. lifted its stake in Tempus AI by 23.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after acquiring an additional 821,490 shares during the period. Amova Asset Management Americas Inc. grew its holdings in Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after acquiring an additional 821,490 shares in the last quarter. Eagle Health Investments LP purchased a new position in Tempus AI during the 1st quarter valued at about $11,588,000. Swiss National Bank increased its position in Tempus AI by 0.3% during the 1st quarter. Swiss National Bank now owns 183,500 shares of the company’s stock valued at $8,298,000 after purchasing an additional 600 shares during the period. Finally, Aristotle Atlantic Partners LLC bought a new stake in shares of Tempus AI in the 1st quarter valued at about $6,179,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations. Tempus reported adjusted earnings of $0.07 per share versus the expected $0.09 loss, while revenue rose 23.1% year over year to $411.54 million, slightly above the $409.39 million consensus. The narrower loss and strong top-line growth were the primary catalysts for the stock’s advance. Tempus Reports Third Quarter 2026 Results
• Positive Sentiment: Management raised its 2026 revenue outlook. Tempus now expects approximately $1.60 billion to $1.605 billion in 2026 revenue and continues to target about $65 million in adjusted EBITDA. Investors were encouraged by growth in the Data and Applications segment, which expanded 33% and carries gross margins above 71%, as well as the company’s collaboration with Bristol Myers Squibb. Tempus 2026 Revenue Outlook
• Positive Sentiment: Analyst and trading signals improved. Needham raised its price target from $75 to $89 and maintained a Buy rating. Trading activity also showed elevated call-option demand, while Cathie Wood’s Ark Investment Management reportedly purchased about $11.2 million of TEM shares, adding to bullish sentiment.
• Neutral Sentiment: Analyst views remain mixed. UBS reiterated a Hold rating with an $80 price target, citing solid oncology execution but weaker hereditary testing. This suggests the earnings beat was encouraging, but some analysts remain cautious about the pace and quality of growth. Tempus UBS Rating
• Negative Sentiment: Personalis acquisition risks remain. Reports highlight potential challenges integrating Personalis, including execution complexity and the possibility that deal-related costs or operational disruption could weigh on future performance. Personalis Integration Risks

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.